Saturday, March 15, 2025, Seattle, Washington, 12:30 PM – 2:00 PM Pacific Time (3:30 PM – 5:00 PM Eastern Time)

Cases from the Community: Investigators Discuss the Optimal Clinical Care of Patients with HER2-Positive Gynecologic Cancers

An Independent CME Symposium During the 2025 SGO Annual Meeting on Women’s Cancer®

Register for in-person Register for webcast

Location
Seattle Convention Center
705 Pike Street
Seattle, Washington
Phone: (206) 694-5000

Program Schedule — Pacific Time
12:00 PM – 12:30 PM — Registration and Lunch Buffet
12:30 PM – 2:00 PM — Educational Meeting

Meeting Room
Room 6AB – Level 6

There is no registration fee for this event. For the in-person symposium in Seattle, preregistration is required as seating is limited.  
 
Faculty
Kathleen N Moore, MD, MS
Deputy Director
Virginia Kerley Cade Chair in Developmental Therapeutics
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University
of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Board of Directors, ASCO
Oklahoma City, Oklahoma

Alessandro D Santin, MD
Professor
Department of Obstetrics and Gynecology
Co-Chief, Gynecologic Oncology
Yale University School of Medicine
New Haven, Connecticut

Moderator
David M O’Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio




This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Program Schedule — Pacific Time
12:00 PM – 12:30 PM — Registration and Lunch Buffet
12:30 PM – 2:00 PM — Educational Meeting

Module 1: Strategies to Identify Patients with HER2-Positive Gynecologic Cancers

  • Incidence of HER2 expression documented among various gynecologic cancer subtypes
  • Definition of HER2 positivity in the pivotal DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd)
  • Appropriate integration of HER2 immunohistochemistry testing into routine gynecologic oncology practice
  • Potential utility of other testing methods, such as next-generation sequencing and liquid biopsy, to identify patients with advanced gynecologic cancers who might benefit from HER2-targeted therapy
  • Optimal source material for and timing of HER2 testing for advanced gynecologic cancers

Module 2: Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers

  • Published research studies with HER2-targeted strategies, such as trastuzumab and pertuzumab/trastuzumab, for advanced endometrial cancer
  • Limited clinical trial database surrounding the use of HER2-targeted therapy for other advanced gynecologic cancers
  • Key efficacy outcomes achieved with T-DXd among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study
  • Recent FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for the management of advanced gynecologic cancers
  • Other novel agents and strategies under evaluation for patients with HER2-positive gynecologic cancers

Module 3: Identification and Management of Adverse Events (AEs) with T-DXd

  • Spectrum and incidence of common (eg, gastrointestinal [GI] toxicities, myelosuppression) and more serious (eg, interstitial lung disease [ILD], cardiac toxicities) treatment-emergent AEs observed with T-DXd
  • Recommendations for monitoring and immediate reporting of symptoms of ILD with T-DXd
  • Strategies to manage T-DXd-associated ILD; indications for restarting T-DXd after resolution of symptoms
  • Appropriate monitoring of complete blood counts and left ventricular ejection fraction during therapy with T-DXd
  • Recommended algorithms for mitigating and managing cardiac toxicities, cytopenias, GI side effects and other complications of T-DXd
  • Initial dosing of T-DXd and dose-modification strategies for patients with treatment-related toxicities

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the prevalence and relevance of HER2 amplification/overexpression in various gynecologic cancers, and consider the implications for biomarker assessment and clinical management.
  • Evaluate published research findings with established HER2-targeted therapies for patients with HER2-positive gynecologic cancers, and assess the current role of various agents and regimens.
  • Recall available data with novel HER2-targeted antibody-drug conjugates for HER2-positive ovarian, endometrial and cervical cancers, and optimally integrate these agents into the care of appropriately selected patients.
  • Appraise the side effects associated with various HER2-directed therapies commonly employed in the care of patients with gynecologic cancers, and use this information to develop supportive therapeutic plans for those undergoing treatment with these agents or regimens.
  • Recall the design of ongoing clinical trials evaluating novel HER2-directed agents and strategies for advanced HER2-positive gynecologic cancers, and counsel appropriately selected patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY Dr Santin has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr MooreAdvisory Committees: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Blueprint Medicines, Caris Life Sciences, Corcept Therapeutics, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Allarity Therapeutics, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics.

MODERATOR Dr O'MalleyAdvisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Seattle Convention Center
705 Pike Street
Seattle, WA 98101
Phone: (206) 694-5000

Meeting Room
Room 6AB – Level 6

Directions
The Seattle Convention Center, formerly the Washington State Convention Center, is the main venue for the 2025 SGO Annual Meeting on Women’s Cancer.

 
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. For the in-person symposium in Seattle, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 SGO Annual Meeting on Women’s Cancer®.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.